Alagille Syndrome
Oncology·MeSH: Alagille Syndrome
Prevalence
5.0 / 100K
5 drugs in development·4 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| livmarli | Mirum Pharmaceuticals, Inc. (MIRM) |
Phase 3(1)
| Drug | Company |
|---|---|
| bylvay | ALBIREO PHARMA, INC. (ALBO) |
Unknown(2)
Phase 4(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Alagille Syndrome?
BioSniper tracks 5 drugs in development for Alagille Syndrome across 4 companies.
How many clinical trials target Alagille Syndrome?
There are 5 clinical trials targeting Alagille Syndrome tracked by BioSniper.
What is the prevalence of Alagille Syndrome?
The estimated prevalence of Alagille Syndrome is approximately 5.0 per 100,000 population.
Deep-dive into Alagille Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis